Samantha

A quick overview of other recent news relating to diabetes management and/or CGMs.

A look at the company's dramatic share price drop, iLet patient numbers, CGM partnership with Abbott & the outlook for rollout in the UK/EU. Beta Bionics, maker of the iLet® Bionic Pancreas, has experienced a turbulent start to 2026 as its share price slid amid concerns over lower than expected numbers of new-starts and patient-reported safety patterns raising questions. iLet user base & new patient starts Image courtesy of Beta Bionics Adoption data from Beta Bionics show rapid early...

What longer-wear monitoring, fewer sensor changes and tighter integration could mean for future CGM and pump choices. Image courtesy of Senseonics Senseonics has announced that their first commercial patient is now using the Eversense 365 CGM integrated with Sequel MedTech’s twiist™ hybrid-closed loop insulin delivery system, marking an important step in the development of longer-term diabetes technology. This is the first time a 365-day CGM has been paired with a hybrid-closed loop system,...